Annual report pursuant to Section 13 and 15(d)

Intangibles, net (Narrative) (Details)

v3.23.1
Intangibles, net (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
May 13, 2021
Dec. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]      
Purchase of intangible asset   $ 0 $ 400
Qbrexza | Journey | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Purchase of intangible asset $ 12,500    
Payment of Upfront Fees $ 12,500    
Percentage of royalty amounts diminution in the event of loss of exclusivity 50.00%    
Intangible assets, amortization period 7 years    
Qbrexza | Achievement of Certain Sales Milestones [Member] | Journey | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Payments of milestones $ 144,000    
Qbrexza | Minimum | First Two Years [Member] | Journey | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Asset purchase agreement, percentage of royalties 30.00%    
Qbrexza | Minimum | Period of Eight Years, After First Two Years [Member] | Journey | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Asset purchase agreement, percentage of royalties 12.00%    
Qbrexza | Maximum | First Two Years [Member] | Journey | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Asset purchase agreement, percentage of royalties 40.00%    
Qbrexza | Maximum | Period of Eight Years, After First Two Years [Member] | Journey | Dermira, Inc. a subsidiary of Eli Lilly [Member]      
Finite-Lived Intangible Assets [Line Items]      
Asset purchase agreement, percentage of royalties 19.00%